Climb Bio Balance Sheet Health
Financial Health criteria checks 6/6
Climb Bio has a total shareholder equity of $222.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $226.0M and $3.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$223.14m |
| Equity | US$222.28m |
| Total liabilities | US$3.74m |
| Total assets | US$226.02m |
Recent financial health updates
Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Feb 01
We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully
Jun 24We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Mar 08We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Nov 18Recent updates
Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Sep 23Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value
Jun 28Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation
Feb 01We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully
Jun 24We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Mar 08We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate
Nov 18Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09
Aug 15Eliem to discontinue development of lead asset as mid-stage pain trial fails
Aug 02SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating
Jul 11Financial Position Analysis
Short Term Liabilities: CLYM's short term assets ($226.0M) exceed its short term liabilities ($3.7M).
Long Term Liabilities: CLYM has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CLYM is debt free.
Reducing Debt: CLYM has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CLYM has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CLYM is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 0.9% per year.